Clinical Trial Update: An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease. [Phase 3]

View source ↗

Summary

An open-label, multi-center expanded-access Phase 3 trial of subcutaneous pasireotide in patients with Cushing's disease has completed with results posted in 20…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cushing Disease

Drugs mentioned

• Signifor (pasireotide) (pasireotide)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Cushing's Disease | Phase 3 | Status: COMPLETED | Results posted: 2018-06-19